Translate

Global Pulmonary Arterial Hypertension (PAH) Information and Market Trend : Opportunities and Forecasts (2016-2021)

"Global Pulmonary Arterial Hypertension (PAH) Market (By Drug Class, By Region, By Country): Opportunities and Forecasts (2016-2021) - (By Drug Class -Endothelin Receptor Antagonists, Prostacyclin & Prostacyclin Analogs, Phosphodiesterase V Inhibitors, Others; By Region-North America, Europe, APAC, Latin America, MEA; By Country- USA, Canada, UK, Germany, Japan, Brazil, South Africa)" The Report covers current Industries Trends, Worldwide Analysis, Global Forecast, Review, Share, Size, Growth, Effect.

Description-

A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of the global Pulmonary Arterial Hypertension (PAH) market on the basis of Drug Class (Endothelin Receptor Antagonists, Prostacyclin, Prostacyclin Analogs, Phosphodiesterase V Inhibitors, Others), By Region (North America, Europe, APAC, Latin America, MEA) and By Country (USA, Canada, UK, Germany, Japan, Brazil, South Africa).


The report suggests that rising development of pipeline drugs in PAH combined with the growing awareness of the disease majorly in developed countries has resulted in the growth of PAH market. Also, the market for Pulmonary Arterial Hypertension (PAH) is growing moderately due to newer launches of pipeline drugs that target different pathways to supress the symptoms of the disease. Early diagnosis of the disease has played a pivotal role in number of patients undergoing treatment.
Among the drug classes, the market is expected to be driven by ERAs. However, growing number of drugs under prostacyclin are expected to witness tremendous growth in the forecast period.

While developed regions will continue to dominate the market in terms of revenue, emerging nations are expected to respond to the market optimistically due to the developing healthcare infrastructure and rising focus on healthcare among the growing middle class population. Global Pulmonary Arterial Hypertension Market is forecasted to grow at a CAGR of 4.95% during 2016 – 2021F, on account of rising prevalence of the PAH disease among the population.

North America region remains the major market followed by Europe in the actual period. In the forecast period, APAC region will witness strong growth driven by the countries such as India and China.

According to Azoth Analytics research report, Global Pulmonary Arterial Hypertension Market: Trends, Opportunities and Forecasts (2016-2021), Global Pulmonary Arterial Hypertension market is projected to exhibit a CAGR of over ~4.95% during 2016 - 2021. On the basis of market segment, Global Pulmonary Arterial Hypertension Market has been segmented By Drug Class (Endothelin Receptor Antagonists, Prostacyclin, Prostacyclin Analogs, Phosphodiesterase V Inhibitors, Others; By Region-North America, Europe, APAC, Latin America, MEA; By Country- USA, Canada, UK, Germany, Japan, Brazil, South Africa)
Scope of the Report

The report provides Segmentation by Drug Class
  • Endothelin receptor antagonists
  • Prostacyclin and Prostacyclin Analogs
  • Phosphodiesterase V Inhibitors 
  • Others 
The report provides coverage by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa (MEA)
The report provides coverage by Country
  • USA
  • Canada 
  • UK
  • Germany
  • Japan
  • Brazil
  • South Africa
Customization of the Report
  • The report could be customized according to the client’s specific research requirements. No additional cost will be required to pay for limited additional research.



Comments

Post a Comment